期刊
DIGESTIVE DISEASES AND SCIENCES
卷 61, 期 7, 页码 1888-1894出版社
SPRINGER
DOI: 10.1007/s10620-016-4100-y
关键词
Gastric mucosa; Gastroesophageal reflux disease; Potassium-competitive acid blocker; Rat; Vonoprazan; TAK-438
资金
- Takeda Pharmaceutical Company Limited
Vonoprazan fumarate (TAK-438) is a novel potassium-competitive acid blocker that appears to exert a longer/more potent antisecretory effect than lansoprazole due to high accumulation/slow clearance from the gastric glands. However, there is no direct evidence that vonoprazan selectively accumulates in gastric parietal cells of gastric glands. To investigate the distribution of radioactivity in the rat stomach after single intravenous administration of [H-3]-labeled vonoprazan. Autoradioluminography of the stomach revealed that at 5 h after administration, radioactivity levels in the corpus mucosal layer was higher than radioactivity levels in the muscular layer, pylorus, and forestomach. At 24 h, although overall radioactivity was significantly decreased, the highest radioactivity was still observed in the mucosal layer. Accumulation of radioactivity in gastric parietal cells was quantitatively analyzed using microautoradiography. The number of silver granules in parietal cells from vonoprazan-injected rats was higher than in cells from a saline-injected rat. At 24 h, the number of granules was approximately at 20 % of the number of granules at 5 h. There was no clear deposition of granules in other components. At 5 h, radioactivity was measured at 1.799 A mu g Eq/g in the stomach and 0.172 A mu g Eq/mL in plasma. After 24 h, radioactivity had decreased to 0.584 A mu g Eq/g in the stomach and 0.078 A mu g Eq/mL in plasma. Vonoprazan selectively accumulates in gastric parietal cells in the mucosal layer of the rat stomach after intravenous administration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据